L’étude clinique du mois. Étude SURMOUNT-OSA : Le tirzépatide▼ améliore le syndrome d’apnée/hypopnée obstructive du sommeil chez le sujet avec obésité.

Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is developed as once-weekly subcutaneous injection. It has been developed in two huge research clinical programmes, SURPASS in type 2 diabetes and SURMOUNT in obesity. Obesity is often complicated by an obstructive sleep apnoea (OSA), which is associated with an increased morbidity and mortality. The controlled study SURMOUNT-OSA has been carried out in people with obesity and OSA, possibly already treated with a continuous positive airway pressure (CPAP). When compared to placebo, tirzepatide (10 or 15 mg/week) reduces body weight, diminishes the frequency and severity of sleep apnoea episodes, dampens hypoxia burden, lowers arterial blood pressure, reduces systemic inflammation and, in fine, improves the parameters of sleep quality reported by patients. Tirzepatide is indicated in the management of people with obesity or overweight who present at least one weight-related comorbidity factor among which OSA.